Related Experiment Videos
The role of low-molecular-weight heparins in arterial diseases: optimizing antithrombotic therapy
1Division of Cardiology, Hahnemann University Hospital, Philadelphia, PA 19102-1192, USA.
Insights
Optimized medical therapy, including low-molecular-weight heparins (LMWHs), improves outcomes for acute coronary syndromes. LMWHs offer enhanced efficacy over unfractionated heparin (UFH) without increasing bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) require optimized medical therapy for improved outcomes and cost-effectiveness.
- Standard treatments like aspirin and unfractionated heparin (UFH) have limitations in preventing recurrent ischemic events.
Purpose of the Study:
- To evaluate the efficacy and safety of newer antithrombotic regimens, specifically low-molecular-weight heparins (LMWHs), in managing ACS.
- To compare LMWHs with standard UFH in patients with unstable angina and non-Q wave myocardial infarction (UA/NQMI).
Main Methods:
- Review of current evidence on antithrombotic therapies for ACS.
- Analysis of studies evaluating LMWHs in UA/NQMI, other arterial diseases, and as adjunctive therapy with thrombolytics.
- Ongoing studies investigating LMWHs in atrial fibrillation.
Main Results:
- Low-molecular-weight heparins (LMWHs) demonstrate improved efficacy compared to unfractionated heparin (UFH) in UA/NQMI.
- LMWHs do not increase the risk of major bleeding complications.
- LMWHs show promise in various arterial conditions and as adjunctive therapy.
Conclusions:
- All patients with acute coronary syndromes should receive optimized medical therapy, including LMWHs, for better clinical outcomes.
- LMWHs represent a more aggressive and effective antithrombotic strategy compared to UFH.
- Further research is ongoing to explore the full potential of LMWHs in cardiovascular medicine.
Abstract:
On the basis of current evidence, all patients with acute coronary syndromes should receive optimized medical therapy, whether or not they ultimately undergo an invasive revascularization procedure, to improve both clinical outcomes and cost effectiveness. While standard aspirin and unfractionated heparin (UFH) have improved short-term outcomes, they do not eliminate the risk of recurrent ischemic episodes. The recent introduction of platelet fibrinogen receptor antagonists and low-molecular-weight heparins (LMWHs) has offered an opportunity to develop more aggressive antithrombotic regimens. The LMWHs have been thoroughly evaluated in unstable angina and non-Q wave myocardial infarction (UA/NQMI), and have demonstrated improved efficacy compared to standard UFH, without an increase in major complications caused by bleeding. Experience has also been gathered using LMWHs in other arterial diseases (such as pregnant patients with prosthetic heart valves) and as an adjunctive therapy with thrombolytics for acute myocardial infarction. Lastly, studies are currently underway evaluating LMWHs in patients with atrial fibrillation.